FDA Approves First Gene Therapy Zolgensma (Onasemnogene Abeparvovec-xioi) for Spinal Muscular Atrophy
TUESDAY, May 28, 2019 -- The first gene therapy has been approved to treat children younger than 2 years with spinal muscular atrophy (SMA), the U.S. Food and Drug Administration announced Friday.
Zolgensma (onasemnogene abeparvovec-xioi), an...
Source: Drugs.com - Daily MedNews - Category: General Medicine Source Type: news
More News: Children | Food and Drug Administration (FDA) | Gene Therapy | General Medicine | Genetics | Spinal Muscular Atrophy